These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Web-Based Tool (FH Family Share) to Increase Uptake of Cascade Testing for Familial Hypercholesterolemia: Development and Evaluation. Bangash H; Makkawy A; Gundelach JH; Miller AA; Jacobson KA; Kullo IJ JMIR Hum Factors; 2022 Feb; 9(1):e32568. PubMed ID: 35166678 [TBL] [Abstract][Full Text] [Related]
4. Use of a chatbot to increase uptake of cascade genetic testing. Schmidlen T; Jones CL; Campbell-Salome G; McCormick CZ; Vanenkevort E; Sturm AC J Genet Couns; 2022 Oct; 31(5):1219-1230. PubMed ID: 35616645 [TBL] [Abstract][Full Text] [Related]
5. Utilizing innovative implementation strategies for familial hypercholesterolemia: Implementation outcomes from the IMPACT-FH study. Campbell-Salome G; Morgan KM; Gabriel J; McGowan MP; Walters NL; Brangan A; Tricou EP; Rahm AK; Sturm AC; Jones LK J Clin Lipidol; 2024; 18(5):e832-e843. PubMed ID: 39278768 [TBL] [Abstract][Full Text] [Related]
6. Family cascade screening for equitable identification of familial hypercholesterolemia: study protocol for a hybrid effectiveness-implementation type III randomized controlled trial. Johnson C; Chen J; McGowan MP; Tricou E; Card M; Pettit AR; Klaiman T; Rader DJ; Volpp KG; Beidas RS Implement Sci; 2024 Apr; 19(1):30. PubMed ID: 38594685 [TBL] [Abstract][Full Text] [Related]
7. Motivating cascade testing for familial hypercholesterolemia: applying the extended parallel process model for clinician communication. Campbell-Salome G; Walters NL; Ladd IG; Sheldon A; Ahmed CD; Brangan A; McMinn MN; Rahm AK; Schwartz MLB; Tricou E; Fisher CL; Sturm AC Transl Behav Med; 2022 Jul; 12(7):800-809. PubMed ID: 35429393 [TBL] [Abstract][Full Text] [Related]
8. The Impact of Proband Indication for Genetic Testing on the Uptake of Cascade Testing Among Relatives. Schmidlen TJ; Bristow SL; Hatchell KE; Esplin ED; Nussbaum RL; Haverfield EV Front Genet; 2022; 13():867226. PubMed ID: 35783293 [TBL] [Abstract][Full Text] [Related]
9. A proof-of-concept study of cascade screening for Familial Hypercholesterolemia in the US, adapted from the Dutch model. McGowan MP; Cuchel M; Ahmed CD; Khera A; Weintraub WS; Wilemon KA; Ahmad Z Am J Prev Cardiol; 2021 Jun; 6():100170. PubMed ID: 34327496 [TBL] [Abstract][Full Text] [Related]
10. Genetic Testing for Familial Hypercholesterolemia: Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2022; 22(3):1-155. PubMed ID: 36158868 [TBL] [Abstract][Full Text] [Related]
11. Perspectives from individuals with familial hypercholesterolemia on direct contact in cascade screening. Schwiter R; Brown E; Murray B; Kindt I; Van Enkevort E; Pollin TI; Sturm AC J Genet Couns; 2020 Dec; 29(6):1142-1150. PubMed ID: 32223038 [TBL] [Abstract][Full Text] [Related]
12. Optimizing communication strategies and designing a comprehensive program to facilitate cascade testing for familial hypercholesterolemia. Campbell-Salome G; Jones LK; Walters NL; Morgan KM; Brangan A; Ladd IG; McGowan MP; Wilemon K; Schmidlen TJ; Simmons E; Schwartz MLB; McMinn MN; Tricou E; Rahm AK; Ahmed CD; Sturm AC BMC Health Serv Res; 2023 Apr; 23(1):340. PubMed ID: 37020233 [TBL] [Abstract][Full Text] [Related]
13. Cascade testing for elevated lipoprotein(a) in relatives of probands with familial hypercholesterolaemia and elevated lipoprotein(a). Chakraborty A; Pang J; Chan DC; Ellis KL; Hooper AJ; Bell DA; Burnett JR; Moses EK; Watts GF Atherosclerosis; 2022 May; 349():219-226. PubMed ID: 34862044 [TBL] [Abstract][Full Text] [Related]
14. A randomized controlled trial of genetic testing and cascade screening in familial hypercholesterolemia. Ajufo E; deGoma EM; Raper A; Yu KD; Cuchel M; Rader DJ Genet Med; 2021 Sep; 23(9):1697-1704. PubMed ID: 34040191 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of cascade genetic testing for familial hypercholesterolemia in the United States: A simulation analysis. Jackson CL; Huschka T; Borah B; Agre K; Zordok M; Farwati M; Moriarty J; Kullo IJ Am J Prev Cardiol; 2021 Dec; 8():100245. PubMed ID: 34485965 [No Abstract] [Full Text] [Related]
16. Value of Measuring Lipoprotein(a) During Cascade Testing for Familial Hypercholesterolemia. Ellis KL; Pérez de Isla L; Alonso R; Fuentes F; Watts GF; Mata P J Am Coll Cardiol; 2019 Mar; 73(9):1029-1039. PubMed ID: 30846097 [TBL] [Abstract][Full Text] [Related]
17. Acceptability, Appropriateness, and Feasibility of Automated Screening Approaches and Family Communication Methods for Identification of Familial Hypercholesterolemia: Stakeholder Engagement Results from the IMPACT-FH Study. Jones LK; Walters N; Brangan A; Ahmed CD; Gatusky M; Campbell-Salome G; Ladd IG; Sheldon A; Gidding SS; McGowan MP; Rahm AK; Sturm AC J Pers Med; 2021 Jun; 11(6):. PubMed ID: 34205662 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of cascade testing strategies in relatives for familial hypercholesterolemia: A systematic review and meta-analysis. Leonardi-Bee J; Boateng C; Faria R; Eliman K; Young B; Qureshi N Atherosclerosis; 2021 Dec; 338():7-14. PubMed ID: 34753031 [TBL] [Abstract][Full Text] [Related]
19. Reverse cascade screening for familial hypercholesterolemia in high-risk Chinese families. Wu X; Pang J; Wang X; Peng J; Chen Y; Wang S; Watts GF; Lin J Clin Cardiol; 2017 Nov; 40(11):1169-1173. PubMed ID: 29168983 [TBL] [Abstract][Full Text] [Related]
20. Facilitating family communication of familial hypercholesterolemia genetic risk: Assessing engagement with innovative chatbot technology from the IMPACT-FH study. Walters NL; Lindsey-Mills ZT; Brangan A; Savage SK; Schmidlen TJ; Morgan KM; Tricou EP; Betts MM; Jones LK; Sturm AC; Campbell-Salome G PEC Innov; 2023 Dec; 2():100134. PubMed ID: 37214500 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]